US COVID-19 Treatment Remdesivir 'Recall'

Glass Particles Found in Remdesivir... 55,000 Vials (11,000 Patient Doses) Recalled
Injection Containing Glass Particles May Lead to Death

[Asia Economy International Department Reporter] Glass particles have been found in the COVID-19 treatment injection drug Remdesivir.

[Image source=Reuters Yonhap News]

On the 4th (local time), according to the Washington Post (WP) and others, the American pharmaceutical company Gilead has recalled bottles of Remdesivir sufficient to treat 11,000 hospitalized COVID-19 patients (55,000 vials) in the United States.

Gilead stated in a press release that customer complaints about glass particles being observed in Remdesivir were received, and an investigation confirmed this fact. The problematic vials subject to the recall have been distributed nationwide in the U.S. since last October.

Gilead explained, "Administering injections containing glass particles can cause inflammation or swelling and may block the heart, lungs, or cerebral blood vessels, leading to stroke and potentially death," but so far, no reports of adverse effects have been received.

Gilead said that since they have sufficient stockpiles of COVID-19 treatments, this recall will not affect the supply of treatments to the U.S. and other countries.

Remdesivir can be used for children aged 12 and older and adults, and is typically administered once daily via intravenous injection for up to 10 days.

This content was produced with the assistance of AI translation services.